CAR-T's greatest successes have been in blood cancers, where tumor cells circulate and share a clean target like CD19. Solid tumors — which make up the majority of cancer deaths — have proven far tougher. But a new generation of research is steadily pushing the boundary.
Why Solid Tumors Are Harder
Three challenges explain the gap. First, it is difficult to find an antigen found on tumor cells but not on essential healthy tissue (the "on-target, off-tumor" problem). Second, solid tumors build a hostile microenvironment that can suppress infused CAR-T cells. Third, physical barriers and tumor heterogeneity make it hard for the cells to penetrate and persist.
Promising Targets Emerging
Researchers are attacking these problems with smarter targets and designs:
- Claudin18.2 — expressed in many gastric and pancreatic cancers; among the most advanced solid-tumor CAR-T programs.
- GPC3 (Glypican-3) — studied in hepatocellular carcinoma (liver cancer).
- EGFRvIII, GD2 — explored in glioblastoma and neuroblastoma respectively.
Blood vs. Solid: Where CAR-T Stands
Approved: B-cell leukemias, lymphomas (CD19) and multiple myeloma (BCMA). Investigational: gastric, pancreatic, liver, brain and other solid tumors — mostly via clinical trials rather than standard approval.
What This Means for Patients
For patients with solid tumors, CAR-T is not yet a standard option outside of trials. But the pace of progress is real, and clinical trials at leading centers — including in China — are opening doors for carefully selected cases. A record review can determine whether a trial might be appropriate.
Our Role
CAR-T Therapy China tracks the evolving landscape so international patients understand both the approved options for blood cancers and the trial possibilities for solid tumors. We help map each case to the right center and the right protocol.